Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.59 |
| ▸ | LPL | P06858 | 12/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | PYCR1 | P32322 | 3/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19421728 | 0.89 | LIPG (0.60) | LIPGLPLPYCR1F11 | |
| SCHEMBL29888970 | 0.86 | LIPG (0.60) | LIPGLPLCHRNB2CHRNA4PYCR1 | |
| SCHEMBL2587679 | 0.86 | LIPG (0.60) | LIPGLPLCHRNB2CHRNA4PYCR1 | |
| SCHEMBL19421732 | 0.86 | LIPG (0.65) | LIPGLPLPYCR1 | |
| Hydrochloric Acid SCHEMBL2006790 | 0.85 | LIPG (0.58) | LIPGLPLCHRNB2CHRNA4F11 | |
| SCHEMBL19430450 | 0.82 | LIPG (0.50) | LIPGLPLPYCR1 | |
| SCHEMBL18332737 | 0.81 | LIPG (0.69) | LIPGLPLF11 | |
| SCHEMBL3039403 | 0.80 | LIPG (0.63) | LIPGLPLF11 | |
| SCHEMBL306766 | 0.79 | SIGMAR1 (0.54) | LIPGLPL | |
| SCHEMBL4604189 | 0.79 | LIPG (0.52) | LIPGLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442974-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| CN-109071545-B | Novel pyrazolopyrimidine derivatives | 拜耳动物保健有限责任公司 | 2021-08-03 | — | — | CN | disclosed |
| US-11001590-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| US-11001590-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| US-10934301-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-03-02 | — | — | US | disclosed |
| US-10934301-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-03-02 | — | — | US | disclosed |
| US-20200299299-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-20200299299-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-20200239482-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-07-30 | — | — | US | disclosed |
| US-20200239482-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-07-30 | — | — | US | disclosed |
| US-10604525-B2 | Pyrazolopyrimidine derivatives | BAYAL ANIMAL HEALTH GMBH (DE) | 2020-03-31 | — | — | US | disclosed |
| US-20190071447-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2019-03-07 | — | — | US | disclosed |
| US-20190071447-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604525-B2 | Pyrazolopyrimidine derivatives | P2RX5, RECQL, P2RX1 | LIPG 4735/4885LPL 4111/4885CHRNB2 3776/4885 |
| US-11001590-B2 | Pyrazolopyrimidine derivatives | P2RX5, RECQL, P2RX1 | LIPG 4740/4885LPL 4139/4885CHRNB2 3730/4885 |
| US-20190071447-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | LIPG 4735/4885LPL 4111/4885CHRNB2 3776/4885 |
| US-20200239482-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | LIPG 4740/4885LPL 4139/4885CHRNB2 3730/4885 |
| US-10934301-B2 | Pyrazolopyrimidine derivatives | P2RX5, RECQL, P2RX1 | LIPG 4740/4885LPL 4139/4885CHRNB2 3730/4885 |
| US-20200299299-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | LIPG 4779/4885LPL 4399/4885CHRNB2 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.